Sherif Abouelhadid

Dr. Sherif Abouelhadid


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Journal of Medical Microbiology
Verified
Journal Article
Open access
VTVanessa S. Terra
Vanessa S. Terra
DMDominic C. Mills
Dominic C. Mills
LYLaura E. Yates
Laura E. Yates
Sherif AbouelhadidSherif Abouelhadid
Sherif Abouelhadid
JCJon Cuccui
Jon Cuccui
BWBrendan W. Wren
Brendan W. Wren
The discovery of the Campylobacter jejuni N-linked glycosylation system combined with its functional expression in Escherichia coli marked the dawn of a new era in glycoengineering. The process, termed protein glycan coupling technology (PGCT), has, in particular, been applied to the development of glycoconjugate vaccines. In this review, we highlight recent technical developments in this area, including the first structural determination of the coupling enzyme PglB, the use of glycotags for optimal glycan attachment and the possible applications of other glycosylation systems and how these may improve and extend PGCT.

30 April 2019 in mBio
Verified
Journal Article
Open access
PDF file
Sherif AbouelhadidSherif Abouelhadid
Sherif Abouelhadid
SNSimon J. North
Simon J. North
PHPaul Hitchen
Paul Hitchen
PVPrerna Vohra
Prerna Vohra
CCCosmin Chintoan-Uta
Cosmin Chintoan-Uta
BWBrendan W Wren
Brendan W Wren
Advances in genomics and mass spectrometry have revealed several types of glycosylation systems in bacteria. However, why bacterial proteins are modified remains poorly defined. Here, we investigated the role of general N- linked glycosylation in a major food poisoning bacterium, Campylobacter jejuni . The aim of this study is to delineate the direct and indirect effects caused by disrupting this posttranslational modification. To achieve this, we employed a quantitative proteomic strategy to monitor alterations in the C. jejuni proteome. Our quantitative proteomic results linked general protein N- glycosylation to maintaining proteome stability. Functional analyses revealed novel roles for bacterial N- glycosylation in modulating multidrug efflux pump, enhancing nitrate reduction activity, and promoting host-microbe interaction. This work provides insights on the importance of general glycosylation in proteins in maintaining bacterial physiology, thus expanding our knowledge of the emergence of posttranslational modification in bacteria.

22 December 2020 in mBio
Verified
Journal Article
Open access
PDF file
Sherif AbouelhadidSherif Abouelhadid
Sherif Abouelhadid
JRJohn Raynes
John Raynes
Tam BuiTam Bui
Tam Bui
JCJon Cuccui
Jon Cuccui
BWBrendan W Wren
Brendan W Wren
Nearly all bacterial species have at least a single glycosylation system, but the direct effects of these posttranslational protein modifications are unresolved. Glycoproteome-wide analysis of several bacterial pathogens has revealed general glycan modifications of virulence factors and protein assemblies. Using Campylobacter jejuni as a model organism, we have studied the role of general N- linked glycans in the multidrug efflux pump commonly found in Gram-negative bacteria. We show, for the first time, the direct link between N -linked glycans and multidrug efflux pump activity. At the protein level, we demonstrate that N -linked glycans play a role in enhancing protein thermostability and mediating the assembly of the multidrug efflux pump to promote antimicrobial resistance, highlighting the importance of this posttranslational modification in bacterial physiology. Similar roles for glycans are expected to be found in other Gram-negative pathogens that possess general protein glycosylation systems.

1 June 2018 in Vaccine
Verified
Journal Article
Open access
JHJenny A. Herbert
Jenny A. Herbert
EKEmily J. Kay
Emily J. Kay
SFSian E. Faustini
Sian E. Faustini
ARAlex Richter
Alex Richter
Sherif AbouelhadidSherif Abouelhadid
Sherif Abouelhadid
TMTimothy J. Mitchell
Timothy J. Mitchell
Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Although this is a vaccine preventable disease, S. pneumoniae still causes over 1 million deaths per year, mainly in children under the age of five. The biggest disease burden is in the developing world, which is mainly due to unavailability of vaccines due to their high costs. Protein polysaccharide conjugate vaccines are given routinely in the developed world to children to induce a protective antibody response against S. pneumoniae. One of these vaccines is Prevnar13, which targets 13 of the 95 known capsular types. Current vaccine production requires growth of large amounts of the 13 serotypes, and isolation of the capsular polysaccharide that is then chemically coupled to a protein, such as the diphtheria toxoid CRM197, in a multistep expensive procedure. In this study, we design, purify and produce novel recombinant pneumococcal protein polysaccharide conjugate vaccines in Escherichia coli, which act as mini factories for the low-cost production of conjugate vaccines. Recombinant vaccine efficacy was tested in a murine model of pneumococcal pneumonia; ability to protect against invasive disease was compared to that of Prevnar13. This study provides the first proof of principle that protein polysaccharide conjugate vaccines produced in E. coli can be used to prevent pneumococcal infection. Vaccines produced in this manner may provide a low-cost alternative to the current vaccine production methodology.

1 January 2017 in Open Biology
Verified
Journal Article
Open access
JCJon Cuccui
Jon Cuccui
VTVanessa S. Terra
Vanessa S. Terra
JBJanine T Bossé
Janine T Bossé
ANAndreas Naegeli
Andreas Naegeli
Sherif AbouelhadidSherif Abouelhadid
Sherif Abouelhadid
OCon behalf of the BRaDP1T Consortium
on behalf of the BRaDP1T Consortium
Actinobacillus pleuropneumoniae is a mucosal respiratory pathogen causing contagious porcine pleuropneumonia. Pathogenesis studies have demonstrated a major role for the capsule, exotoxins and outer membrane proteins. Actinobacillus pleuropneumoniae can also glycosylate proteins, using a cytoplasmic N -linked glycosylating enzyme designated NGT, but its transcriptional arrangement and role in virulence remains unknown. We investigated the NGT locus and demonstrated that the putative transcriptional unit consists of rimO , ngt and a glycosyltransferase termed agt. From this information we used the A. pleuropneumoniae glycosylation locus to decorate an acceptor protein, within Escherichia coli, with a hexose polymer that reacted with an anti-dextran antibody. Mass spectrometry analysis of a truncated protein revealed that this operon could add up to 29 repeat units to the appropriate sequon. We demonstrated the importance of NGT in virulence, by creating deletion mutants and testing them in a novel respiratory cell line adhesion model. This study demonstrates the importance of the NGT glycosylation system for pathogenesis and its potential biotechnological application for glycoengineering.

22 January 2025 in npj Vaccines
Verified
Journal Article
Open access
PDF file
SCSowmya Ajay Castro
Sowmya Ajay Castro
IPIan J. Passmore
Ian J. Passmore
DNDidier Ndeh
Didier Ndeh
HSHelen Alexandra Shaw
Helen Alexandra Shaw
ARAlessandro Ruda
Alessandro Ruda
HDHelge C. Dorfmueller
Helge C. Dorfmueller
Group A Streptococcus (Strep A) is a human-exclusive bacterial pathogen killing annually more than 500,000 patients, and no current licensed vaccine exists. Strep A bacteria are highly diverse, but all produce an essential, abundant, and conserved surface carbohydrate, the Group A Carbohydrate, which contains a rhamnose polysaccharide (RhaPS) backbone. RhaPS is a validated universal vaccine candidate in a glycoconjugate prepared by chemical conjugation of the native carbohydrate to a carrier protein. We engineered the Group A Carbohydrate biosynthesis pathway to enable recombinant production using the industry standard route to couple RhaPS to selected carrier proteins within Escherichia coli cells. The structural integrity of the produced recombinant glycoconjugate vaccines was confirmed by Nuclear Magnetic Resonance (NMR) spectroscopy and mass spectrometry. Purified RhaPS glycoconjugates elicited carbohydrate-specific antibodies in mice and rabbits and bound to the surface of multiple Strep A strains of diverse M-types, confirming the recombinantly produced RhaPS glycoconjugates as valuable vaccine candidates.